Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 15.41 as of 2026-10-06T15:47:42.055Z.
Consensus retrieved: 2026-10-06T14:46:26.110Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:47:42.055Z.
Quote observation: 2026-10-06T15:45:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9698da87e99c3f510f9e6b066a48d58a9a509647b73979b6621194e77f4a0ea7
Forward PE Ratio (15.41) = Dated Quote Price ($34.96) / Consensus Forward EPS ($2.27)
FORWARD PE RATIO
15.41
SECTOR MEDIAN · HEALTHCARE
19.78
median of 171 covered companies
CURRENT VS SECTOR MEDIAN
-22.09%
vs the sector median at left
Omnicell, Inc.
Market Cap
$1.59B
Forward PE Ratio
15.41
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Omnicell, Inc. (OMCL) | $1.59B | 15.41 |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.62B | N/A |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 7.73 |
| Innoviva, Inc. (INVA)vs › | $1.55B | 8.65 |
| uniQure N.V. (QURE)vs › | $1.54B | N/A |
| Nutex Health, Inc. (NUTX)vs › | $1.54B | 8.05 |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.64B | 32.68 |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.64B | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 50.97 |
| Phibro Animal Health Corporation (PAHC)vs › | $1.51B | 10.68 |
Trailing P/E
41.4
reported TTM EPS
Forward P/E
15.4
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.27 implies +170.2% EPS growth vs the reported trailing $0.84.
At the dated quote price of $34.96, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.27 | $2.13 – $2.42 | 5 | 15.4x |
| 2027-12-31 | $2.09 | $1.56 – $2.59 | 5 | 16.7x |
| 2028-12-31 | $2.46 | $2.25 – $2.67 | 2 | 14.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
